205 related articles for article (PubMed ID: 24831239)
21. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Yang C; Wang H; Zhang B; Chen Y; Zhang Y; Sun X; Xiao G; Nan K; Ren H; Qin S
J Exp Clin Cancer Res; 2016 Sep; 35(1):158. PubMed ID: 27737687
[TBL] [Abstract][Full Text] [Related]
22. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
[TBL] [Abstract][Full Text] [Related]
23. Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions.
Chen L; Chen DT; Kurtyka C; Rawal B; Fulp WJ; Haura EB; Cress WD
J Biol Chem; 2012 Nov; 287(48):40106-18. PubMed ID: 23060449
[TBL] [Abstract][Full Text] [Related]
24. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Fichtner I; Rolff J; Soong R; Hoffmann J; Hammer S; Sommer A; Becker M; Merk J
Clin Cancer Res; 2008 Oct; 14(20):6456-68. PubMed ID: 18927285
[TBL] [Abstract][Full Text] [Related]
25. Piceatannol Enhances the Antitumor Efficacy of Gemcitabine in Human A549 Non-Small Cell Lung Cancer Cells.
Xu B; Tao ZZ
Oncol Res; 2014; 22(4):213-217. PubMed ID: 26351210
[TBL] [Abstract][Full Text] [Related]
26. Combined effects of resveratrol and paclitaxel on lung cancer cells.
Kubota T; Uemura Y; Kobayashi M; Taguchi H
Anticancer Res; 2003; 23(5A):4039-46. PubMed ID: 14666716
[TBL] [Abstract][Full Text] [Related]
27. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells.
Honore S; Kamath K; Braguer D; Horwitz SB; Wilson L; Briand C; Jordan MA
Cancer Res; 2004 Jul; 64(14):4957-64. PubMed ID: 15256469
[TBL] [Abstract][Full Text] [Related]
28. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.
Smit EF; van Meerbeeck JP; Lianes P; Debruyne C; Legrand C; Schramel F; Smit H; Gaafar R; Biesma B; Manegold C; Neymark N; Giaccone G;
J Clin Oncol; 2003 Nov; 21(21):3909-17. PubMed ID: 14581415
[TBL] [Abstract][Full Text] [Related]
29. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
30. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
[TBL] [Abstract][Full Text] [Related]
32. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
de Fraipont F; Levallet G; Creveuil C; Bergot E; Beau-Faller M; Mounawar M; Richard N; Antoine M; Rouquette I; Favrot MC; Debieuvre D; Braun D; Westeel V; Quoix E; Brambilla E; Hainaut P; Moro-Sibilot D; Morin F; Milleron B; Zalcman G;
Clin Cancer Res; 2012 May; 18(10):2976-86. PubMed ID: 22434665
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Rodriguez J; Cortes J; Calvo E; Azinovic I; Fernandez-Hildago O; Martinez-Monge R; Garzon C; de Irala J; Martinez-Aguillo M; Ramon Y Cajal T; Brugarolas A
Cancer; 2000 Dec; 89(12):2622-9. PubMed ID: 11135224
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia Induces Multidrug Resistance via Enhancement of Epidermal Growth Factor-Like Domain 7 Expression in Non-Small Lung Cancer Cells.
Shen X; Zhi Q; Wang Y; Li Z; Zhou J; Huang J
Chemotherapy; 2017; 62(3):172-180. PubMed ID: 28351036
[TBL] [Abstract][Full Text] [Related]
35. Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer.
Divers SG; Spencer SA; Carey D; Busby EM; Hyatt MD; Robert F
J Clin Oncol; 2005 Sep; 23(27):6664-73. PubMed ID: 16170174
[TBL] [Abstract][Full Text] [Related]
36. Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.
Duarte ML; de Moraes E; Pontes E; Schluckebier L; de Moraes JL; Hainaut P; Ferreira CG
Cancer Lett; 2009 Jun; 279(1):57-64. PubMed ID: 19217709
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors.
Skobeleva N; Menon S; Weber L; Golemis EA; Khazak V
Mol Cancer Ther; 2007 Mar; 6(3):898-906. PubMed ID: 17363484
[TBL] [Abstract][Full Text] [Related]
38. Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance.
Zeng HZ; Qu YQ; Liang AB; Deng AM; Zhang WJ; Xiu B; Wang H; Wang H
Neoplasma; 2011; 58(5):449-54. PubMed ID: 21745000
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in in vitro and in vivo human non-small cell lung cancer models.
Gao ZW; Zhang DL; Guo CB
Curr Cancer Drug Targets; 2010 Nov; 10(7):705-15. PubMed ID: 20578985
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
